32.20

0.53% 0.17

After Hours: 32.20

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $32.20, with a volume of 3.44M. It is up +0.53% in the last 24 hours and down -4.62% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$32.03

Open:

$31.99

24h Volume:

3.44M

Relative Volume:

0.77

Market Cap:

$13.95B

Revenue:

$2.27B

Net Income/Loss:

$1.15B

P/E Ratio:

12.63

EPS:

2.55

Net Cash Flow:

$2.80B

1W Performance:

-1.23%

1M Performance:

-4.62%

6M Performance:

+19.48%

1Y Performance:

+14.55%

1-Day Range:

$31.84

$32.30

1-Week Range:

$31.58

$32.73

52-Week Range:

$24.05

$34.20

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1154)

Industry

Biotechnology (677)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2025-02-11

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	32.20	13.95B	2.27B	1.15B	2.80B	2.55
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

Apr 25, 2025

Canada Pension Plan Investment Board Buys 39,070 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Guggenheim Capital LLC Sells 82,768 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Adage Capital Partners GP L.L.C. Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

GMT Capital Corp Increases Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Boosted by Barclays PLC - MarketBeat

Apr 25, 2025

Walleye Capital LLC Buys Shares of 25,124 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Dark Forest Capital Management LP Has $3.42 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Jump Financial LLC Makes New $2.09 Million Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Invesco Ltd. Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 25, 2025

Apr 24, 2025

Bridgewater Associates LP Acquires New Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Apr 24, 2025

Royalty Pharma plc Plans Quarterly Dividend of $0.22 (NASDAQ:RPRX) - MarketBeat

Apr 24, 2025